新型药物在多发性骨髓瘤中的高效分配：一项正在进行的工作。
Efficient allocation of novel agents in multiple myeloma: a work in progress.
机构信息
Institute for Medical Technology Assessment, Erasmus University, P.O. Box 1738, S000DR Rotterdam, The Netherlands.
出版信息
Oncologist. 2013;18(1):5-7. doi: 10.1634/theoncologist.2012-0484. Epub 2013 Jan 8.
Abstract
This commentary examines key questions regarding the use of novel agents in multiple myeloma, addressed by two articles in this month's issue.
摘要
这篇评论探讨了本月这两篇文章中涉及的新型药物在多发性骨髓瘤中的应用所涉及的关键问题。
相似文献
1
Efficient allocation of novel agents in multiple myeloma: a work in progress.新型药物在多发性骨髓瘤中的高效分配：一项正在进行的工作。
Oncologist. 2013;18(1):5-7. doi: 10.1634/theoncologist.2012-0484. Epub 2013 Jan 8.
2
Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.新型多发性骨髓瘤抗肿瘤药物：对其治疗价值和经济价值证据的综述。
Expert Rev Anticancer Ther. 2012 Jun;12(6):839-54. doi: 10.1586/era.12.42.
3
Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective.新型药物在 Medicare 多发性骨髓瘤患者中的成本效益：来自美国支付方的观点。
J Manag Care Spec Pharm. 2017 Aug;23(8):831-843. doi: 10.18553/jmcp.2017.23.8.831.
4
Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.达雷妥尤单抗与泊马度胺治疗复发/难治性多发性骨髓瘤的成本效益分析。
Am J Hematol. 2019 Mar;94(3):E68-E70. doi: 10.1002/ajh.25372. Epub 2018 Dec 18.
5
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.法国医院复发性或难治性多发性骨髓瘤的治疗管理及相关直接费用评估：一项多中心回顾性队列研究。
J Clin Pharm Ther. 2011 Feb;36(1):19-26. doi: 10.1111/j.1365-2710.2009.01153.x.
6
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.硼替佐米联合美法仑和泼尼松与沙利度胺联合美法仑和泼尼松或来那度胺联合美法仑和泼尼松联合来那度胺维持治疗在初治多发性骨髓瘤美国的成本效益。
Oncologist. 2013;18(1):27-36. doi: 10.1634/theoncologist.2011-0380. Epub 2013 Jan 8.
7
Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?多发性骨髓瘤新型治疗药物经济学评价的系统评价：报告质量如何？
J Clin Pharm Ther. 2016 Apr;41(2):189-97. doi: 10.1111/jcpt.12384. Epub 2016 Mar 23.
8
Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.复发/难治性多发性骨髓瘤患者治疗历程中的成本抵消。
Clin Ther. 2019 Mar;41(3):477-493.e7. doi: 10.1016/j.clinthera.2019.01.009. Epub 2019 Feb 14.
9
10
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.硼替佐米与地塞米松联用环磷酰胺或来那度胺治疗新诊断多发性骨髓瘤的疗效、医疗资源利用及成本
Leukemia. 2016 Apr;30(4):995-8. doi: 10.1038/leu.2015.225. Epub 2015 Aug 14.
引用本文的文献
1
The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan.台湾南部移植不适用的骨髓瘤患者接受硼替佐米联合沙利度胺加地塞米松（VTD）或硼替佐米联合美法仑加泼尼松（VMP）治疗的成本效益分析
J Pers Med. 2022 Jan 19;12(2):130. doi: 10.3390/jpm12020130.
2
Long-Term Effectiveness and Cost Effectiveness of Multiple Myeloma Treatment Strategies for Elderly Transplant-Ineligible Patients in Serbia.塞尔维亚老年不适宜移植的多发性骨髓瘤治疗策略的长期有效性和成本效益
Zdr Varst. 2020 Apr 6;59(2):83-91. doi: 10.2478/sjph-2020-0011. eCollection 2020 Jun.
3
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.双复发和/或难治性多发性骨髓瘤：临床结果与实际医疗费用
PLoS One. 2015 Sep 14;10(9):e0136207. doi: 10.1371/journal.pone.0136207. eCollection 2015.
本文引用的文献
1
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.硼替佐米联合美法仑和泼尼松与沙利度胺联合美法仑和泼尼松或来那度胺联合美法仑和泼尼松联合来那度胺维持治疗在初治多发性骨髓瘤美国的成本效益。
Oncologist. 2013;18(1):27-36. doi: 10.1634/theoncologist.2011-0380. Epub 2013 Jan 8.
2
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.新型药物治疗与其他疗法治疗多发性骨髓瘤的医疗成本和资源利用，包括患者负担：基于真实世界理赔数据的研究结果。
Oncologist. 2013;18(1):37-45. doi: 10.1634/theoncologist.2012-0113. Epub 2013 Jan 8.
3
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?新型药物在初诊多发性骨髓瘤中的双联、三联或四联方案？
Hematology Am Soc Hematol Educ Program. 2012;2012:354-61. doi: 10.1182/asheducation-2012.1.354.
4
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.新型抗肿瘤药物时代复发/难治性多发性骨髓瘤的真实世界医疗成本。
J Clin Pharm Ther. 2013 Feb;38(1):41-7. doi: 10.1111/jcpt.12020. Epub 2012 Nov 6.
5
Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands.肿瘤学中结局研究的实际可行性：在荷兰评估药物使用和成本效益方面的经验教训。
Eur J Cancer. 2013 Jan;49(1):8-16. doi: 10.1016/j.ejca.2012.06.010. Epub 2012 Jul 16.
6
Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.新型多发性骨髓瘤抗肿瘤药物：对其治疗价值和经济价值证据的综述。
Expert Rev Anticancer Ther. 2012 Jun;12(6):839-54. doi: 10.1586/era.12.42.
7
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.硼替佐米-沙利度胺-地塞米松作为自体造血干细胞移植后巩固治疗优于沙利度胺-地塞米松治疗新诊断多发性骨髓瘤患者。
Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12.
8
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.硼替佐米、地塞米松、环磷酰胺和来那度胺联合治疗初治多发性骨髓瘤的随机、多中心、2 期研究（EVOLUTION）。
Blood. 2012 May 10;119(19):4375-82. doi: 10.1182/blood-2011-11-395749. Epub 2012 Mar 15.
9
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.硼替佐米联合来那度胺与烷化剂和皮质类固醇在多发性骨髓瘤一线治疗中的临床疗效和成本效益：系统评价和经济评估。
Health Technol Assess. 2011 Dec;15(41):1-204. doi: 10.3310/hta15410.
10
Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.复发和难治性多发性骨髓瘤的治疗策略：新型药物时代的药物序贯和“再治疗”方法重点关注。
Leukemia. 2012 Jan;26(1):73-85. doi: 10.1038/leu.2011.310. Epub 2011 Oct 25.
Zotero 插件